Results 211 to 220 of about 155,399 (295)

Macrophage microRNA-150 promotes pathological angiogenesis as seen in age-related macular degeneration [PDF]

open access: yes, 2018
Agarwal   +11 more
core   +2 more sources

Irigenin Modulates BL‐Induced Pyroptosis in Retinal Pigment Epithelial Cells Through p38 MAPK and NFκB Pathways

open access: yesJournal of Biochemical and Molecular Toxicology, Volume 40, Issue 2, February 2026.
Irigenin alleviates blue light‐induced RPE cell damage by inhibiting NLRP3 inflammasome and p38/NF‐κB signalling, showing potential for AMD prevention. ABSTRACT Age‐related macular degeneration (AMD), a primary cause of vision loss among older adults, is strongly associated with inflammatory processes.
I‐Li Su   +9 more
wiley   +1 more source

Functional analyses of rare genetic variants in complement component C9 identified in patients with age-related macular degeneration [PDF]

open access: bronze, 2018
Mariann Kremlitzka   +9 more
openalex   +1 more source

Progress in RNA‐Targeted Therapeutics for Human Diseases

open access: yesMedComm, Volume 7, Issue 2, February 2026.
RNA‐targeted therapies are revolutionizing molecular medicine by transitioning from a “protein‐centric” focus to an “RNA‐regulatory network” approach. Leveraging RNA's diverse roles in gene regulation, signaling, and epigenetic modifications, advanced platforms such as ASOs, siRNA, miRNA, mRNA, aptamers, shRNA, and CRISPR/Cas systems are enabling ...
Wangzheqi Zhang   +10 more
wiley   +1 more source

Proteomic Insights into the Retinal Response to PRGF in a Mouse Model of Age-Related Macular Degeneration. [PDF]

open access: yesMedicina (Kaunas)
Anitua E   +7 more
europepmc   +1 more source

Intravitreal bevacizumab (Avastin) for the treatment of choroidal neovascularization in age-related macular degeneration: results from 118 cases

open access: green, 2007
Krishnappa C. Madhusudhana   +7 more
openalex   +1 more source

Optimized ACE2‐Fc fusion proteins with picomolar neutralization activity against highly evolved SARS‐CoV‐2 variants

open access: yesProtein Science, Volume 35, Issue 2, February 2026.
Abstract The rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has compromised the efficacy of many authorized monoclonal antibody products. This highlights the need for alternative strategies, especially for vulnerable populations such as immunocompromised individuals.
Ferran Abancó   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy